Rapid Micro Biosystems Earnings Call Transcripts
Fiscal Year 2026
-
Automation of microbial quality control is driving faster, more reliable pharmaceutical manufacturing, with strong recurring revenue from consumables and services. 2026 guidance targets 16% revenue growth, margin expansion, and significant runway for customer and market penetration, supported by strategic partnerships and operational efficiencies.
-
Rapid automation of pharmaceutical microbial quality control is driving strong recurring revenue and margin growth, supported by global expansion and a strategic partnership with MilliporeSigma. AI-driven data insights and regulatory trends are expected to accelerate adoption, with significant impact projected from 2026 onward.
-
Rapid automation of pharmaceutical microbial quality control is driving strong recurring revenue and margin expansion, supported by global adoption, a robust land-and-expand strategy, and a growing partnership with MilliporeSigma. Continued innovation and operational efficiency position the business for further growth and break-even in the near term.
Fiscal Year 2025
-
Q4 revenue grew 37% year-over-year to $11.3M, driven by record system placements and strong consumable growth. 2026 guidance projects $37–$41M revenue, 30–38 system placements, and gross margin expansion to ~20%, supported by cost reductions and strategic partnerships.
-
Growth Direct's automation is driving faster, more accurate microbial quality control, with expanding adoption among top pharma companies and increasing multi-system orders. The MilliporeSigma partnership is set to boost global reach and margins, while ongoing efficiency initiatives and incremental investments support a positive margin outlook and sustained 20% revenue growth.
-
Q3 revenue grew 3% to $7.8M, driven by record consumable sales and strong recurring revenue. A record multi-system order and MilliporeSigma collaboration are set to boost 2026 growth and margins. Full-year revenue guidance was raised to at least $33M.
-
Rapid Micro Biosystems is driving automation in microbial quality control, achieving strong revenue growth and expanding its global footprint, especially through a strategic partnership with Merck. The company targets 25–30% annual growth and aims for 50% gross margins by 2027.
-
Q2 2025 revenue rose 10% year-over-year to $7.3M, with recurring revenue up 15% and gross margin improving to 4%. A new $45M term loan was secured, and full-year guidance was reaffirmed, though system placements are expected at the low end due to trade uncertainties.
-
First quarter revenue grew 28% year-over-year to $7.2 million, with record service revenue and significant gross margin improvement. Guidance for 2025 is reaffirmed, with strong customer demand, ongoing cost reductions, and a promising MilliporeSigma collaboration supporting a positive outlook.
-
The company is driving automation in pharmaceutical microbial quality control, achieving strong growth and expanding its customer base among top pharma firms. Strategic partnerships and new product launches are enhancing market reach, recurring revenue, and gross margins, with further gains expected through 2027.
-
Rapid Micro Biosystems showcased strong revenue growth, improved margins, and expanding global adoption of its automated Growth Direct platform, supported by major partnerships with MilliporeSigma and Lonza. The company is leveraging AI and innovation to drive efficiency and aims to become the industry standard in pharmaceutical quality control.
-
Rapid Micro Biosystems reported strong 2024 growth, with $28M in revenue and record Q4 results, driven by recurring revenue and global expansion. The Growth Direct platform automates pharmaceutical QC, improving data integrity and efficiency, with innovations like Rapid Sterility and a key collaboration with Lonza.
Fiscal Year 2024
-
Fourth quarter revenue grew 30% year-over-year to $8.2 million, with record gross margin improvement and strong recurring revenue. A new global partnership with MilliporeSigma is set to expand market reach and drive efficiencies, with major impact expected in 2026.
-
Growth Direct is modernizing pharmaceutical microbial QC with automation, driving efficiency, data integrity, and global adoption. Multi-system orders and new offerings like sterility testing are fueling growth, with biologics and cell therapies contributing higher recurring revenue. Gross margin improvements and expanded commercial reach support a positive 2025 outlook.
-
Q3 revenue grew 24% year-over-year to $7.6M, with record system placements and positive gross margin. Full-year revenue guidance of at least $27M is reaffirmed, and the company targets positive cash flow by 2027 without new financing.
-
Rapid Micro Biosystems highlighted strong revenue growth, expanding adoption of its Growth Direct platform, and operational efficiency initiatives targeting cash flow breakeven by 2027. The company is focused on high-value pharma segments, new applications, and margin improvement.
-
Q2 revenue grew 32% year-over-year to $6.6 million, exceeding guidance, with record system placements and improved gross margins. The Operational Efficiency Program aims for positive cash flow by 2027, supported by strong customer demand and expanding product adoption.